Skip to main content

Table 1 Patient characteristics

From: Thymostimulin in advanced hepatocellular carcinoma: A phase II trial

Characteristics (n = 44)

Patients

 

Male/female, n (%)

37/7 (84/16)

Median age, years (range)

69 (41–80)

Median weight, kg (range)

74 (58–123)

Origin of liver disease, n (%)

 

Alcohol abuse

20 (46)

HBV/HCV

8 (18)

NASH

5 (11)

Cryptogenic

11 (25)

Tumor stage, n (%)

 

Liver cirrhosis

37 (84)

Child classification A/B/C

23/9/5 (52/21/11)

Okuda stage I/II/III

13/28/3 (29/64/7)

CLIP 0/1–3/4–6

2/35/7 (5/79/16)

α-FP (ng/ml), n (%)

 

< 400

29 (66)

400- 10000

8 (18)

> 10000

7 (16)

Tumor characteristics, n (%)

 

Ascites

13 (30)

Portal vein thrombosis

14 (32)

Multifocal tumor manifestation

38 (86)

Extrahepatic metastases

9 (21)

Previous treatment, n (%)

 

(combination possible)

 

Surgery

4 (9)

Radiofrequency ablation

5 (11)

Transarterial chemoembolisation

17 (39)

Systemic chemotherapy

4 (9)